2005

  • Mentlein, R. (2005). Dipeptidyl-peptidase IV and aminopeptidase P: molecular switches of NPY/PYY receptor affinities. In: "The NPY Family of Peptides in Immune Disorders, Inflammation, Angiogenesis and Cancer" (Z. Zukowska, G. Z. Feuerstein, Eds.). Birkhäuser-Verlag, Basel, pp. 75-84.
  • Varoga, D., Pufe, T., Mentlein, R., Kohrs, S., Grohmann, S., Tillmann, B., Hassenpflug, J., and Paulsen, F. (2005). Expression and regulation of antimicrobial peptides in articular joints. Ann. Anat. 187, 499-508.
  • Pufe, T., Kurz, B., Petersen, W., Varoga, D., Mentlein, R., Kulow, S., Lemke, A., and Tillmann, B. (2005). The influence of biomechanical parameters on the expression of VEGF and endostatin in the bone and joint system. Ann. Anat. 187, 461-72.
  • Pufe, T., Petersen, W., Mentlein, R., and Tillmann, B. (2005). The role of vasculature and angiogenesis for the pathogenesis of degenerative tendons disease. Scand. J. Med. Sci. Sports 15, 211-22.
  • Ludwig, A., Schulte, A., Schnack, C., Hundhausen, C., Reiss, K., Brodway, N., Held-Feindt, J., and Mentlein, R. (2005). Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells. J. Neurochem. 93, 1293-1303.
  • Varoga, D., Pufe, T., Harder, J., Schröder, J.-M., Mentlein, R., Meyer-Hoffert, U., Goldring, M. B., Tillmann, B., and Paulsen, F. (2005). Human ?-defensin-3 mediates tissue remodelling processes in articular cartilage by increasing metalloproteinases and reducing their endogenous inhibitors. Arthritis Rheumatism 52, 1736-1745.
  • Huang, H., Held-Feindt, J., Buhl, R., Mehdorn, H. M., Mentlein, R. (2005). Expression of VEGF and its receptors in different brain tumors. Neurological Res. 27, 371-377.
  • Gebhardt, M., Mentlein, R., Schaudig, U., Pufe, T., Recker, K., Nolle, B., Al-Samir, K., Geerling, G., and Paulsen, F.P. (2005). Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Ophthalmology 112, 1023-1030.
  • Mest, H.-J., and Mentlein, R. (2005). Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 48, 616-620.
  • Mentlein, R. (2005). Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs. Expert Opin. Invest. Drugs 14, 57-64.
  • Mentlein, R., and Pufe, T. (2005). New functions of angiogenic peptides in osteoarthritic cartilage. Current Rheumatology Reviews 1, 37-43.